The estimated Net Worth of Michael Steinmetz is at least $3.56 Milione dollars as of 15 February 2006. Michael Steinmetz owns over 166,667 units of Cortexyme Inc stock worth over $3,523,260 and over the last 20 years Michael sold CRTX stock worth over $36,762.
Michael has made over 2 trades of the Cortexyme Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently Michael bought 166,667 units of CRTX stock worth $1,000,002 on 15 February 2006.
The largest trade Michael's ever made was buying 166,667 units of Cortexyme Inc stock on 15 February 2006 worth over $1,000,002. On average, Michael trades about 56,212 units every 187 days since 2004. As of 15 February 2006 Michael still owns at least 1,806,800 units of Cortexyme Inc stock.
You can see the complete history of Michael Steinmetz stock trades at the bottom of the page.
Michael's mailing address filed with the SEC is C/O MPM ASSET MANAGEMENT, 200 CLARENDON STREET, 54TH FLOOR, BOSTON, MA, 02116.
Over the last 21 years, insiders at Cortexyme Inc have traded over $59,595,534 worth of Cortexyme Inc stock and bought 19,273,711 units worth $164,053,955 . The most active insiders traders include & Johnson Johnson & Johnson..., Farmaceutici Sp A Chiesi e Ansbert Gadicke. On average, Cortexyme Inc executives and independent directors trade stock every 59 days with the average trade being worth of $475,426. The most recent stock trade was executed by Caryn Gordon Mc Dowell on 6 June 2022, trading 10,800 units of CRTX stock currently worth $30,888.
Cortexyme, Inc. is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer's and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial in patients with mild to moderate Alzheimer's disease. Cortexyme is targeting a specific, infectious pathogen found in the brain and other organs and tied to degeneration and inflammation in humans and animal models.
Cortexyme Inc executives and other stock owners filed with the SEC include: